Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use

Broad spectrum systemic antibiotics for hospitalized patients will likely continue to account for most of the novel agents approved under the Qualified Infectious Disease Product (QIDP) designation for the near future, according to data from Scrip sister publication The Pink Sheet's FDA Performance Tracker.

Broad spectrum agents remain the best option for acutely ill patients who cannot wait to begin treatment while bacteria are being identified, even as more targeted approaches to anti-infective therapy...